Barbiturates enhance GABA receptor (sodium-independent) binding at 0°C to bovine brain membranes about 2-fold in chloride-containing buffer but not in chloride-free phosphate or Tris/ citrate buffer. This effect is observed in frozen and thawed, thoroughly washed membranes from various regions of bovine brain as well as washed membranes prepared from unfrozen rat cerebral cortex; it is destroyed by brief treatment of the membranes with the detergent Triton X-100. The enhancement is concentration-dependent, with approximately 250 pM pentobarbital giving 50% of the maximal effect seen with saturating 2 mM barbiturate. This effect is reversed by the GABA chloride channel-blocking drug picrotoxinin in a concentration-dependent manner, with 50% inhibition at 0.6 FM, and also by GABA receptor antagonists, such as bicuculline, which inhibit base line GABA receptor binding. Under similar conditions, benzodiazepines do not perturb GABA binding. The barbiturate enhancement varies with brain region in a manner which does not correlate with overall GABA receptor binding; for example, cerebellum shows poor barbiturate enhancement despite a high level of GABA binding. The anions which support barbiturate interactions with GABA receptor binding in vitro are the same ones shown to be required for barbiturate interactions with benzodiazepine receptor binding (Leeb-Lundberg, F., A. Snowman, and R. W. Olsen (1980) Proc. Natl. Acad. Sci. U. S. A. 77: 7468-7472) and correlated with the permeation of GABAregulated, barbiturate-enhanced inhibitory ion channels measured in vivo. Likewise, the activity of a series of barbiturates to enhance GABA binding shows a specificity and stereospecificity agreeing with that shown for enhancing benzodiazepine binding and correlating with pharmacological activity as nervous system depressants and enhancers of GABA responses. However, the activity of excitatory barbiturates remain to be clarified. These results suggest that there is a receptor site for barbiturates on the GABA. benzodiazepine receptor. chloride ion channel complex, consistent with physiological enhancement of GABA postsynaptic responses by barbiturates. The enhancement of GABA binding by barbiturates appears to involve an increase in the number of binding sites under most assay conditions and using several labeled receptor ligands. The amount of GABA bound to both high and low affinity subpopulations is increased by barbiturates in both equilibrium and kinetic measurements. It is possible that the effect of barbiturates involves an increase in affinity for normally undetectable low affinity (&I 2 1 PM) GABA sites. Low affinity sites are detected under some conditions, and the barbiturate enhancement is then consistent with an increased affinity. Barbiturates enhance GABA binding in a similar manner at 37°C and O"C, but the effect is much greater at 37°C than at 0°C for the analogue piperidine-4-sulfonic acid. This may be related to the differential interactions of GABA analogues with benzodiazepine receptors at different temperatures. The more physiological conditions of temperature and saline appear to be more suitable for physiologically relevant receptor binding studies in vitro.
these drugs (Richards, 1972 , Blaustein, 1968 . Barbiturates enhance the postsynaptic membrane response to GABA (Huang and Barker, 1980; Schulz and Macdonald, 1981; Simmonds, 1981) , which involves a receptor-regulated chloride channel opening (Study and Barker, 1981) . The action of another important group of nervous system depressants, the benzodiazepines, also may involve potentiation of GABA-mediated inhibition (Haefely et al., 1979; Study and Barker, 1981) .
GABA receptor sites can be assayed in vitro by suitable radioactive ligand binding (Olsen et al., 1981b) . GABA receptors have been assayed traditionally in NaCl-free medium (Zukin et al., 1974; to prevent GABA uptake) and in frozen and thawed, thoroughly disrupted, and multiply washed membranes (Enna and Snyder, 1975 ; to remove endogenous inhibitors of GABA binding (Greenlee et al., 1978) including GABA (Napias et al., 1980) , but possibly other materials (Guidotti et al., 1978) ). Under the assay conditions usually employed, barbiturates and benzodiazepines were observed neither to inhibit nor to perturb GABA receptor binding (Olsen et al., 1979) , suggesting that the receptors for both of these classes of drugs are distinct from the GABA receptor site.
Benzodiazepines also can be assayed in vitro by radioactive ligand binding (Squires and Braestrup, 1977) , and benzodiazepine binding is enhanced allosterically in affinity by both GABA agonists (Tallman et al., 1980) and barbiturates (Leeb-Lundberg et al., 1980) and the related drugs, the anxiolytic pyrazolopyridines (Leeb-Lundberg et al., 1981a; Supavilai and Karobath, 1981) . The enhancement of benzodiazepine receptor binding by barbiturates is chemically specific and stereospecific, with potencies of a series of compounds correlating well with pharmacological activity as depressants and potentiators of GABAergic inhibition (Bowery and Dray, 1978) . Barbiturate and pyrazolopyridine enhancement of benzodiazepine binding is inhibited competitively by the GABA chloride channel-blocking convulsant drug picrotoxinin (Leeb-Lundberg et al., 1980 , 1981a and indirectly inhibited by the GABA receptor antagonist bicuculline (Leeb-Lundberg et al., 1981a) . Furthermore, the interaction of barbiturates (Leeb-Lundberg et al., 1980) and pyrazolopyridines (Supavilai and Karobath, 1981) with benzodiazepine receptors is dependent on the presence of chloride or certain other anions. These anions happen to be the same anions which can permeate membrane chloride channels in spinal cord (Araki et al., 1961 ) and brain neurons (Eccles et al., 1977) which are involved in GABAergic postsynaptic inhibitory potentials and which are potentiated by barbiturates (Nicoll et al., 1975) . The drug interactions in vitro are consistent with the existence of a receptor complex which includes receptors for GABA, benzodiazepines, and barbiturates as well as the chloride channel (Olsen, 1981) .
Pyrazolopyridines increase GABA receptor binding in vitro in a chloride-enhanced manner (Placheta and Karobath, 1980 ). The pyrazolopyridines have been shown to perturb benzodiazepine binding at a picrotoxinin-sensitive site which is similar to or identical to the site at which barbiturates perturb benzodiazepine binding (Leeb-Lundberg et al., 1981a) . Like the barbiturates (Ticku and Olsen, 1978) , the pyrazolopyridines (LeebLundberg et al., 1981a) competitively inhibit the binding of ["Hldihydropicrotoxinin at relevant concentrations. Thus, pyrazolopyridines and barbiturates appear to have numerous in vitro actions in common, and therefore, barbiturates also might be expected to perturb GABA binding. Barbiturates have now been observed to enhance GABA binding; initial studies suggest that a gentle membrane preparation is critical for observing this interaction (Willow and Johnston, 1980, 1981a, b, c) . We present here the results of studies on barbiturate enhancement of GABA receptor binding and the conclusion that this effect is optimal in the presence of chloride or certain other anions which are able to permeate GABAregulated chloride channels as mentioned above. This anion specificity further supports the relevance of the barbiturate receptor sites defined by these in vitro effects, both to the GABA receptor.ionophore complex and to the pharmacological actions of barbiturates. Some of the results have been presented in preliminary form (Olsen et al., 1981a; Olsen and Leeb-Lundberg, 1981) . While this paper was in preparation, a report describing similar results appeared (Asano and Ogasawara, 1981) .
Materials and Methods
["HIGABA (50 Ci/mmol) was purchased from Amersham Corp; ["Hlmuscimol (10.3 Ci/mmol), ["Hlpiperidine-4-sulfonic acid (P4S; 35 Ci/mmol), ["HI isoguvacine (24.8 Ci/mmol), and ["H]4, 5, 6, 24. 3 Ci/mmol) were purchased from New England Nuclear. Unlabeled muscimol and P4S were gifts of Dr. P. Copenhagen. Pentobarbital, barbituric acid (DMBB), amobarbital, and secobarbital were gifts of Eli Lilly and Co. Barbital was a gift of Merck; etazolate was a gift of E. R. Squibb & Sons, Inc; mephobarbital and phenobarbital were gifts of Sterling-Winthrop; metharbital was a gift of Abbot Laboratories. Stereoisomers of hexobarbital and mephobarbital were kindly provided by Dr. J. Knabe, Saarbrucken. All other compounds were from commercial sources. Preparation of synaptic membranes. Mammalian brain membranes were prepared and assayed for GABA receptor binding essentially as described previously (Greenlee et al., 1978; Napias et al., 1980; Olsen et al., 1981b; Krogsgaard-Larsen et al., 1981) . Various brain regions from rat (freshly prepared) or cow (frozen in 0.32 M sucrose for up to 6 months at -20°C) were homogenized in 10 vol of 0.32 M sucrose at 0°C by eight passes of a motor-driven Teflon pestle (800 rpm) in a glass homogenizer tube (Thomas). The homogenate was centrifuged for 10 min at 1000 X g in a Beckman centrifuge (52-21) to yield a crude nuclear pellet, which was discarded. The supernatant fraction was centrifuged for 60 min at 150,000 x g to collect the crude mitochondrial, synaptosomal, and microsomal membranes, and this time, the supernatant was discarded. This membrane fraction was disrupted twice with a Tissumizer (Ultra-Turrax, Tekmar Co., Cincinnati, OH) in 20 vol of distilled water and centrifuged at 150,000 x g for 30 min. The resulting pellet was homogenized in 50 mM Tris buffer adjusted to pH 7.1 at 4°C with sodium-free citric acid and frozen at -2OC". These samples were thawed and centrifuged, homogenized in the same buffer, and then frozen again. On the day of the assay, the samples were thawed and Vol. 2, No. 12, Dec. 1982 centrifuged. The pellets were homogenized in the buffer to be used for assays and centrifuged once more, and the resulting pellets were homogenized for assay. Binding assays. GABA receptor binding was measured by centrifugation (Enna and Snyder, 1975; Olsen et al., 1981b; Greenlee et al., 1978) (10 nM) was added with or without 0.1 mM nonradioactive ligands to estimate nondisplaceable binding; in some experiments, the concentration of radiolabeled ligand was varied. Varying concentrations of barbiturates were included in the assays. Triplicate samples of about 1 mg of protein in an assay volume of 1 ml were incubated for 15 min at 0 to 4"C, followed by centrifugation at 50,000 x g for 10 min in a Beckman centrifuge (52-21). The supernatants were discarded and the pellets were rinsed twice superficially with 3 ml of cold buffer. Rinsed pellets were solubilized overnight in 0.20 ml of Soluene 350 (Packard). Radioactivity was counted (Beckman LS-3155T) in 3 ml of toluene containing 0.5% (w/v) of 2,5-diphenyloxazole, with an efficiency of 27%. Protein was measured according to the method of Lowry et al. (1951) . The binding data were analyzed by a nonlinear regression program, using a HP3000 computer to determine affinity constants (KU values) and the quantity of binding sites (B,,,;,,) . The best fits of the data to receptor models, consisting of one binding site or two or three independent sites (Olsen et al., 1981b) , were compared. Experiments were performed using 20 mM KH2POd/K2HP04 buffer containing 50 mM KC1 (pH 7.5). Quadruplicate samples of about 1 mg of protein in an assay volume of 1 ml containing 20 nrvr of radioactive ligand were treated as described below. For measurement of the association rate (on rate), bovine cortex membranes were incubated at 0°C for various periods. The membranes were pelleted by centrifugation for 3 min at 12,800 x g in an Eppendorf microcentrifuge (model 5412). The dissociation rates (off rate) were measured by equilibration of bovine cortex membranes with radioactive ligand for at least 15 min at O"C, after which the incubation media were made 0.1 mM in the corresponding nonradioactive ligand (lo-p1 aliquots in the lml assay volumes) and then centrifuged after further incubation for appropriate times as described above. Background was determined at equilibrium (215 min) with 0.1 mM of nonradioactive ligand. The bulk of the membranes were pelleted within a few seconds, so that the accuracy of the time scale was about +lO set; the variation of the counts per min in any 15-set period (after the first 15 set of dissociation) was less than 5%. The pellets were rinsed superficially, solubilized overnight in 0.1 ml of Soluene 350, and counted as described above.
In some experiments, filtration was employed to separate the bound ligand from free ligand. Membranes were prepared as described above and incubated with radioactive GABA receptor ligands for various times (association rate measurements) or equilibrated for at least 15 min, followed by the addition of a microliter volume of excess nonradioactive ligand for various times (dissociation rate measurements). The samples in quadruplicate were trapped on Whatman GF/B filter paper discs under vacuum and washed with 2 ml of 0.2 M NaCl at 0°C. The filters were dried and radioactivity was measured in 5 ml of New England Nuclear Aquasol:toluene (2:l) with an efficiency of 45%. Background, determined with 0.1 mM nonradioactive GABA, was 30 to 40%.
Results
Barbiturates such as pentobarbital showed a concentration-dependent enhancement of sodium-independent GABA receptor binding in well washed, frozen and thawed membrane fractions of bovine cerebral cortex when using assay buffers containing chloride ions. The enhancement reached a maximum of roughly 100% in the presence of 50 mM KC1 with an apparent EGO value for pentobarbital of 250 PM (Fig. lA ) . The effect of pentobarbital was reversed in a concentration-dependent manner by picrotoxinin with an I& value of 0.8 pM (Fig. 1B ) . Picrotoxinin at concentrations over 1 PM also showed a weak inhibition of base line GABA binding under these assay conditions. The picrotoxinin-like convulsant isopropyl bicyclophosphate and the benzodiazepine R05-3663 at 0.1 mM also completely blocked the effect of 250 PM pentobarbital; as with base line GABA binding, the pentobarbital-enhanced GABA binding also was blocked by bicuculline and strychnine with I&O values of 100 nM and 10 PM, respectively (data not shown). Table I summarizes the effects of several drugs on GABA receptor binding to various brain membrane preparations assayed under various conditions. As reported previously (Olsen et al., 1979) , there was no effect of pentobarbital (500 PM) on GABA binding when assayed in Tris/citrate buffer devoid of sodium chloride. Similarly, there were no significant, concentration-dependent, and reproducible effects on GABA binding measured in Tris/citrate buffer in the presence of the anxiolytic pyrazolopyridine etazolate (10 PM), the barbiturate DMBB (200 PM),  or the benzodiazepine flurazepam (10 FM) ( Table I , line 1). The barbiturates produced a weak inhibition of GABA binding. In Tris/citrate, these agents had no effects on the binding dissociation rate (data not shown), measured as previously described (Olsen et al., 1981b; Krogsgaard-Larsen et al., 1981) . Furthermore, in Tris/citrate, there was not significant perturbation by 500 PM pentobarbital or 10 pM flurazepam of GABA binding curves measured at 20 ligand concentrations (Table II) . Other brain regions gave similar results.
In an assay buffer containing chloride ions, there was significant enhancement of GABA or muscimol binding by pentobarbital, DMBB, and etazolate but not flurazepam (Table I , lines 2 and 3). Flurazepam weakly inhibited GABA binding (120% at 10 PM, but this effect was not seen with another benzodiazepine, diazepam). There was no enhancement of GABA binding by benzodiazepines under any of the assay conditions tested. Inclusion of both pentobarbital and flurazepam together gave enhancement equal to that of pentobarbital alone (3 experiments). GABA receptor binding also was enhanced by pentobarbital but not by flurazepam in other brain regions (Table I, to well washed, frozen and thawed bovine cortex membranes was measured by centrifugation as described under "Materials and Methods." Assays in triplicate were performed at 0°C using 2.5 nM GABA in 20 mM potassium phosphate buffer, pH 7.5, with 50 mM KCl. Standard errors of the mean are indicated in the figure. The results are typical of 3 experiments which varied ~2%. In this experiment, the nondisplaceable background, which was determined in the presence of 0.1 IilM nonradioactive GABA, was 950 + 10 cpm. Specific binding, determined by subtracting the background from the total counts per min pelleted with the membranes, was 1982 * 99 cpm. This is equal to 68% displaceable binding and a signal:noise ratio of 2.1 for the control situation (in the absence of barbiturates or picrotoxinin). cerebellum and brainstem. The magnitude of this effect barbiturate-displaceable C"H]dihydropicrotoxinin binddid not correlate with overall GABA binding, which is ing (Leeb-Lundberg et al., 1981c). Neither did it correlate highest in cerebellum (Greenlee et al., 1978) , nor with with base line benzodiazepine binding nor with barbitu- , 1980; Leeb-Lundberg and Olsen, 1981; Olsen and Leeb-Lundberg, 1981) . Interestingly, the brain regional variation correlated with that fraction of pentobarbital-enhanced benzodiazepine binding which could be blocked by bicuculline (Leeb-Lundberg and Olsen, 1981) . The results shown in Table I The effect of pentobarbital on GABA receptor binding was lost, however, upon treatment of frozen bovine brain membranes with 0.05% Triton X-100 for 30 min at 37"C, followed by washing the membranes and assay in phosphate/chloride buffer at 0°C (Table I , line 8). Table III shows that the half-maximal effect of chloride ions on the pentobarbital enhancement of GABA binding occurred at approximately 30 mM, with at least 100 mM Cl-needed for maximal activation. The ion requirements for barbiturate enhancement of GABA binding are described in Table IV . As in the case of barbiturate enhancement of benzodiazepine binding (Leeb-Lundberg et al., 1980) , the effect requires certain anions, such as chloride, bromide, iodide, perchlorate, thiocyanate, or nitrate, whereas others, such as sulfate, acetate, and propionate, will not substitute.
Sodium, potassium, calcium, or magnesium salts of the active anions (e.g., chloride) were effective, but none of these cations was effective with an inactive anion (e.g., sulfate).
The activity of several barbiturates to enhance GABA binding is shown in Table V (Knabe et al., 1978) . Phenobarbital gave no enhancement of GABA binding under these conditions. At high concentrations, it inhibited GABA binding weakly (20% at 1 mM). Figure 2 indicate that pentobarbital causes an apparent increase in the number of binding sites detected or B,,,, value. In the typical example shown in Figure 2A , the binding of ["HIGABA depicted in a Scatchard plot gives the binding parameters listed in Table IIB . Nonlinear regression computer analysis of the data gives a best fit for two binding sites as previously described (Olsen et al., 1981b) . Pentobarbital-enhanced GABA binding also gives a two-site fit, with similar affinities (KU values are 5 and 150 nM in control and 6 and 200 nM with pentobarbital present), but shows an increase in B,,, from 0.25 to 0.50 pmol/mg of protein for the higher affinity population and an increase from 1.5 to 2.0 pmol/mg for the lower affinity population, giving an overall increase from 1. Experiments A, C, and D were performed at 0°C and experiment B was performed at 37°C. Details are given for the ligand concentrations employed in experiment D as an example: the concentration of radioactive GABA was varied from 0.3 to 10 nM at 10 concentration points, using 0.1 mM nonradioactive GABA at each point to determine the background; then the concentration of nonradioactive GABA was varied using constant radioactive GABA at 10 nM. Some representative values obtained were as follows. At 0.6 nM, 628 cpm + 3% of total ligand "binding" was measured; 176 cpm t-4% of background was determined; the difference of 452 cpm + 4% represents specific binding, corresponding to 72% displacement and a ratio of specific binding to background of 2.6. At 10 nM GABA, the total "binding" was 6683 cpm + 4% and the background was 1932 cpm + 6%; the specific binding therefore was 4751 cpm + 6%, corresponding to 71% displaceable binding and a signal:noise ratio of 2.5; at a concentration of approximately 10 pM GABA, total counts were 2360 cpm f 6% and background was 1932 cpm + 6%, with a difference of specific binding of 428 cpm f 6%, representing 18% displaceable binding and a signal:noise ratio of 0.22. Such values of specific binding were significantly different from zero. Data were analyzed by nonlinear regression as previously described (Olsen et al., 1981b) , giving less weight to those points having a large variance in the mean. (Fig. 20) . This shows significant binding in the 0.1 to 10 PM concentration range and a total B,,, of about 4 pmol/mg. It should be noted that all of the specific GABA binding depicted in Figure 20 is displaceable not only by 0.1 mM nonradioactive GABA but also by 10 PM muscimol, 100 PM P4S, and 100 PM bicuculline; that is, it has receptor-like specificity (Olsen et al., 1979) . Under these experimental conditions, where low affinity sites are detectable in the absence of barbiturates, there is no further increase in B,,, when barbiturates are added, and the increased binding appears to be due to an increase in binding affinity. The computer fit of these expanded binding curves is equally good for three sites (KU values of 10 nM, 50 nM, and 2 PM; standard deviation, 0.96) and for two sites (KU values of 20 nM and 400 nM; standard deviation, 0.98) (without pentobarbital).
In the presence of pentobarbital, at least two sites also are needed to fit the GABA binding data, with less binding in the micromolar range and more in the 10 to 100 nM range. However, the fit for muscimol binding with pentobarbital ( Fig. 2C ; Table ZIG ) is almost as good statistically for one site (KU = 8 nM; B,,, = 2.4 pmol/mg) as it is for two sites, which is also consistent with a shift to high affinity population(s). Thus, the additional GABA receptor binding seen in the presence of pentobarbital involves sites with affinities in the 1 to 100 nM range, similar or perhaps identical in affinity to those seen in the absence of barbiturates.
The kinetics of GABA receptor binding also are consistent with the equilibrium data. As we reported previously (Olsen et al., 1981b) , association and dissociation rates for GABA are biphasic, with slow on and off rates (half-lives of 1 to 4 min) corresponding to the higher affinity binding sites and more rapid rates (half-lives less than 5 set) corresponding to lower affinity binding sites. The dissociation rate for the slow component of [3H]muscimol binding, however, was increased slightly by pentobarbital, decreasing the control half-life from 11.5 to 8 min (Fig. 3A) . In addition to the slow component, a second component Figure 3 . Effect of pentobarbital on the dissociation rate for GABA receptor ligands. A, muscimol; B, P4S. The off rate for GABA receptor ligands was measured by the microcentrifugation method as described under "Materials and Methods." Bovine cortex membranes equilibrated at 0°C with radioactive ligand for 15 min or longer were made 0.1 mM in nonradioactive GABA at time zero and samples were centrifuged at varying times thereafter to determine the dissociation of bound ligand in the presence (0) and absence (0) of 500 pM pentobarbital.
Note that the values are normalized to the percentage of equilibrium values.
was evident, showing a half-life on the order of 10 to 30 sec. The higher affinity ligand, muscimol, apparently has a dissociation rate for the "lower affinity" sites which is slightly slower than that for GABA and P4S. This rate constant still could not be measured accurately by the microcentrifuge method employed, due to an uncertainty of about 10 set in the actual time of quenching. Even allowing for this uncertainty in the early time points, the faster component did not appear to extrapolate through the 100% (zero time) point, suggesting additional binding to a third component which has completed the dissociation reaction in less than 5 sec. This very rapidly dissociating component could correspond to the "very low" affinity sites evident in the equilibrium data shown in Figure 2 , C and D. Filtration assays were employed, but the amount of binding was about 30% lower than that observed with centrifugation, due to loss of rapidly dissociating bound ligand during filter washing. The binding which was retained by filtration was about 80% slowly dissociating component as compared to about 50% in the centrifugation assays. Thus, the more rapid dissociation rates could not be measured, but it was possible to determine that some rapidly dissociating ligand was already lost at the first measurable time, 2 to 3 set after the addition of excess nonradioactive ligand. The data in Figure 3 are normalized and the actual binding is almost 2-fold greater in the presence of pentobarbital. Therefore, more binding to the slower component occurs when pentobarbital is present, but the ratio of slow to fast components decreases slightly (from 39% to 32% for muscimol and from 35% to 28% for P4S), because an even greater increase in the amount of binding to the faster component(s) has occurred. Under these conditions of low ligand concentration, the effect of barbiturate is an apparent increase in the number of binding sites (B,,,) detected for both slow and fast components, as described above. Since the proportion of slow sites did not increase, there could have been no conversion of detectable fast sites into slow sites by pentobarbital. The additional binding to slowly dissociating sites apparently arises from previously undetectable sites. On the other hand, the increase in binding seen with pentobarbital does not involve only fast sites; if it had, the ratio of fast to slow would have increased even more.
This conclusion is supported further by calculating the percentage of enhancement of muscimol binding by pentobarbital at various times during association and dissociation in an experiment such as that shown in Figure 3 .
In the off direction, using an example where pentobarbital induced an 80% enhancement at equilibrium (zero time), this enhancement fell to 40% at the first time point (5 to 10 set) following the addition of excess nonradioactive ligand, indicating that a greater fraction of the enhanced binding showed rapid dissociation than slow dissociation. On the other hand, some enhanced binding also showed slow dissociation, as indicated by the retention of 25% enhancement after 2 min of dissociation, a time when only slow component remains. Likewise, in the on direction, there was considerable enhancement (50%) at 5 set (indicating increased binding primarily to the rapid, low affinity component) but even more enhancement (70%) at 1 to 2 min (indicating increased binding to the slow, high affinity component in addition). Finally, the effect of temperature on the pentobarbital enhancement was examined. Measuring GABA receptor binding at 37°C did not result in any significant changes over parameters determined at 0°C (Table II, B and C) . There is a slight shift to lower affinities (higher Ku values) for the 37°C curves, but two components are still the best fit. Pentobarbital did not affect GABA or mus- Vol. 2, No. 12, Dec. 1982 cimol binding differently at the two temperatures. However, ["H]P4S binding was more enhanced at 37°C than at 0°C (Table II, E and F) , reaching 400% of control at some ligand concentrations.
Discussion
Consistent with physiological evidence that barbiturates enhance GABA-mediated inhibition in the nervous system (Haefely et al., 1979) and biochemical evidence that barbiturates perturb benzodiazepine binding in vitro to receptor sites which are coupled to GABA receptor sites (Olsen, 1981) , barbiturates also directly perturb the binding of GABA receptor ligands. This in vitro interaction was not observed in previous studies using frozen and thawed, thoroughly washed membranes and Tris/ citrate buffer lacking sodium and chloride ions (Olsen et al., 1979) . Barbiturate enhancement of GABA binding in the NaCl-free Tris/citrate buffer was observed with fresh brain membranes prepared with a more gentle procedure (Willow and Johnston, 1980) . We present evidence here that barbiturate enhancement of GABA binding is optimal in the presence of physiological concentrations of chloride ions or certain other anions. This interaction is observed with both fresh membranes and frozen and thawed, thoroughly washed membranes (a procedure whose primary purpose is to remove endogenous GABA from the preparation; Napias et al., 1980). The "gentle" membrane preparation employed by Willow and Johnston (1980, 1981c) might involve retention of some endogenous chloride ions or might, for some other reason, show a less absolute requirement for chloride in the barbiturate-GABA receptor interaction. Barbiturates increase GABA binding to sites having affinities and kinetics similar to those normally detected in the absence of barbiturates, with & values in the 10 to 200 nM range and dissociation rate half-times in the seconds to minutes range. We cannot say for certain whether these "new" sites are the same as or different from those previously described. The "new" sites appear to arise from an increased affinity of GABA binding sites which are normally undetectable (Fig. 2, A and B) or perhaps from sites which are barely detectable (Fig. 2, C  and D) , having Ku values for GABA in the micromolar range and kinetic rates too fast to measure by available techniques. The effect of pentobarbital appears to be an increase in B,,, under conditions where these low affinity sites are not detectable in the control assays.
The enhanced binding of GABA seen with barbiturates was described by Willow and Johnston (1981b) as a decreased dissociation rate for GABA binding to an already slowly dissociating subpopulation, consistent with an increase in affinity for the high affinity subpopulation of GABA receptor binding sites (Willow, 1981) . In our hands, the barbiturate enhancement appears to involve an increase in the number of binding sites showing very slow (minutes) and slow (seconds) dissociation rates, corresponding to affinities in the 1 to 100 nM range. The increase in slowly dissociating (and associating) GABA binding would be consistent with measurements of the chloride ion channels opened by GABA (Study and Barker, 1981) , showing that barbiturates prolong the lifetime of these channels. A reasonable model would equate the time that the chloride channel is open with the time during which the GABA receptor is occupied.
Interestingly, in the same study (Study and Barker, 1981) , benzodiazepines enhanced the frequency of opening rather than the lifetime of GABA-activated chloride channels. Under the same conditions where barbiturates enhanced GABA binding, no significant effects of benzodiazepines were observed, perhaps consistent with the apparent physiological differences in action of the two classes of drugs. Of course, the two drug categories also have other differences in pharmacological action despite the apparent similarities in their involvement with the GABA system. It is also possible that the benzodiazepines perturb a subpopulation of low affinity GABA binding sites which are normally undetectable, and the perturbation is not great enough to make these hypothetical sites detectable. We observed no significant effect of benzodiazepines on GABA binding, even under conditions of high ligand concentration where low affinity sites are detected. In addition, we observed no significant alteration by benzodiazepines of the barbiturate effect on GABA binding, when both drugs were included concurrently. However, this interaction probably is very dependent on the method of membrane preparation and assay. The original report (Guidotti et al., 1978) of benzodiazepine effects on GABA binding was observed only with unwashed membranes suggested to contain a protein which modulated the interactions and which could be removed by thorough washing. Recently, however, several groups have reported enhancement of GABA receptor binding using a variety of membrane preparations (Meiners and Salama, 1982; Ito and Kuriyama, 1982; Skerritt et al., 1982; Matsumoto and Fukuda, 1982) . In all cases, the effects were quite small, and these reports do not agree on which GABA binding sites are affected, the first two describing increased affinity for high affinity sites of less than 1.5-fold and the last two describing an increased affinity for the low affinity sites of less than 2-fold. Ito and Kuriyama (1982) reported that the enhancement persists in detergent-soluble extracts. The difference between these results and those of Guidotti et al. (1978) (who observed an increase in the B,,,, of high affinity sites) and ours (no effect) are unexplained at this time.
The specificity of the barbiturate interaction with GABA receptor binding sites is shown by the chemical specificity and stereospecificity for a series of barbiturates, by the reversal of this effect by picrotoxinin and related convulsants, and by the stimulation of the effect by those anions which are capable of permeating GABA receptor-linked chloride ion channels. As with nervous system depressant action, the potency of a series of barbiturates to enhance GABA binding correlates well with lipid solubility. Thus, the hydrophobic portion of the nerve cell membrane, probably including the fatty acid chains of phospholipids, appears to be involved in the structures which barbiturates must affect in exerting their pharmacological actions as well as their effects on GABA receptor binding. These hydrophobic regions may form the actual site of action ("receptor") for the barbiturates and/or they could form part of the pathway through which the barbiturates must travel to reach their site of action. The site of barbiturate action on GABA binding, as in nervous system depression, could involve lipids but also probably involves protein, due to the stereospecificity of the effect. With the N'-methyl barbiturates, the hypnotic isomers (+)-hexobarbital and (-)-mephobarbital are more potent enhancers of GABA binding than their pharmacologically less active isomers. Furthermore, the interaction of barbiturates with GABA receptor binding (Stephenson and Olsen, 1982 ) and benzodiazepine binding (Stephenson et al., 1982; Davis and Ticku, 1981) is preserved in bile salt, 3-[(3-cholamidopropyl)-dimethylammonio]propanesulfonate, and Lubrol detergent-solubilized preparations of the membrane-binding proteins, although these preparations could contain lipids as well. The barbiturate-GABA-benzodiazepine interactions are still present in the receptor. protein complex partially purified by column chromatography (Stephenson and Olsen, 1982) . Separation of the benzodiazepine binding and barbiturate-sensitive picrotoxinin binding activity by column chromatography has been reported, however (Davis and Ticku, 1981) . It is not yet known why treatment of the membranes with low levels of Triton X-100, while leaving the GABA binding intact, destroys the barbiturate enhancement, but it could be that the Triton X-100 removes protein or lipid components required for the interaction.
The pyrazolopyridines and barbiturates enhance GABA and benzodiazepine receptor binding specifically and do not affect the binding to brain membranes of radioactive ligands for dopamine, opiate, cw-adrenergic, muscarinic, or glycine receptors (Leeb-Lundberg and Olsen, 1982a; Meiners and Salama, 1982) . The chemical specificity for barbiturate enhancement of GABA binding is very similar to that which we reported for the enhancement of benzodiazepine binding (Table V) and has been shown previously to correlate with hypnotic activity and the enhancement of GABA action (Bowery and Dray, 1978; Leeb-Lundberg et al., 1980) . A similar effect of barbiturates on benzodiazepine binding has been reported by at least three other laboratories (Skolnick et al., 1981; Ticku, 1981; Asano and Ogasawara, 1981) .
The barbiturate interaction with GABA receptor binding was suggested by the observation that the pyrazolopyridines enhance GABA binding (Placheta and Karobath, 1980) , since the barbiturates resemble the pyrazolopyridines in causing a chloride-dependent, picrotoxinin-sensitive enhancement of benzodiazepine binding (Supavilai and Karobath, 1981; Leeb-Lundberg et al., 1981a) . Pyrazolopyridines and barbiturates overlap in their pharmacological actions (both are anxiolytic; both enhance GABA responses; Study and Barker, personal communication), but they do not coincide (pyrazolopyridines are not very sedative; Meiners and Salama, 1982) . The similar effects in vitro appear related to the actions of these two classes of drugs on the GABA/benzodiazepine receptor system; it seems reasonable that barbiturates have additional actions in viva which are not shared with pyrazolopyridines.
Furthermore, the in vitro effects of barbiturates and pyrazolopyridines are not equal, differing, for example, in their sensitivity to bicuculline with regard to their enhancement of benzodiazepine binding (Leeb-Lundberg et al., 1981a) and in the interaction with subpopulations of benzodiazepine receptors differing in affinity for ,&carbolines and triazolopyridazine ligands (Leeb-Lundberg and Olsen, 1982b) . Although some of the barbiturates which enhance GABA and benzodiazepine activity are excitatory agents, they are depressants in addition (Huang and Barker, 1980; Knabe et al., 1978) . In fact, all of the active compounds have depressant activity and GABA-enhancing physiological activity which correlates with their activity in vitro to enhance GABA binding (DMBB > secobarbital > pentobarbital = (+)-hexobarbital > (-)-mephobarbital = amobarbital > (-) -hexobarbital > (+)-mephobarbital = phenobarbital = metharbital = barbital), as previously discussed in detail (Olsen and Leeb-Lundberg, 1981; Leeb-Lundberg and Olsen, 1982a (Willow and Johnston, 1981a) . At higher concentrations, pentobarbital was observed to reverse its enhancement, and when the membranes were washed with low levels of Triton X-100, only an inhibition was observed, suggesting that two separate effects are involved (Willow and Johnston, 1981c) . In our hands, using a different membrane preparation as described above, phenobarbital gave no significant enhancement but did give a weak and probably nonspecific inhibition at supramillimolar concentrations. Triton X-100 treatment did eliminate the enhancement of GABA binding by the active barbiturates.
We observed that phenobarbital enhances benzodiazepine binding only slightly but, at 200 ,u~, competitively inhibits the enhancement of benzodiazepine binding by pentobarbital, indicating that phenobarbital binds to the same sites as pentobarbital, but in a different manner (Leeb-Lundberg and Olsen, 1982a) . Since some other nonbarbiturate anticonvulsant agents had a similar, albeit weak, effect (Leeb-Lundberg et al., 1981b) , the different effects of barbiturates used primarily for anticonvulsant activity (e.g., phenobarbital) and those used primarily for hypnotic activity (e.g., pentobarbital) might be related to qualitative differences observed between the two types of drugs in physiological studies of barbiturate action (Schulz and Macdonald, 1981; Simmonds, 1981) . The relevance of anticonvulsant drug interactions with the GABA receptor system also will require further study.
The anion specificity for the enhancement of GABA binding by barbiturates also agrees with that seen for barbiturate (Leeb-Lundberg et al., 1980) and pyrazolopyridine (Supavilai and Karobath, 1981 ) enhancement of benzodiazepine binding as well as with the anion enhancement of base line benzodiazepine binding . This anion specificity has been shown Leeb-Lundberg et al., 1980) to correlate with that of chloride channels involved in postsynaptic inhibitory potentials in spinal cord (Araki et al., 1961) and hippocampus (Eccles et al., 1977) , inhibitory potentials which also are potentiated by barbiturates (Nicoll et al., 1975) . This correspondence in anion specificity seems unlikely to be coincidental and provides further evidence that the in vitro interaction of barbiturates with GABA receptor binding is related to some pharmacological effects of these drugs.
The inhibition by micromolar picrotoxinin of barbiturate enhancement of GABA and benzodiazepine binding is also consistent with the interaction at the GABA receptor. ionophore complex. Barbiturates (Ticku and Olsen, 1978) and pyrazolopyridines (Leeb-Lundberg et al., 1981a) inhibit the binding of ["Hldihydropicrotoxinin at concentrations similar to those affecting GABA and benzodiazepine binding. Since there is not a very good correlation between barbiturate potencies in the latter assays and their inhibition of picrotoxinin binding (LeebLundberg and Olsen, 1982a; Olsen and Leeb-Lundberg, 1981 ), it appears that the picrotoxinin-sensitive barbiturate receptor site which is coupled to the GABA. benzodiazepine receptor complex is a subpopulation of sites labeled by radioactive picrotoxinin.
An interesting brain regional variation was observed for the barbiturate enhancement of GABA receptor binding. Although GABA binding is equal or greater in cerebellum than in cerebral cortex, barbiturate enhancement of GABA binding is much less in cerebellum than in cortex and therefore does not correlate with overall GABA binding. The enhancement may correspond instead with the presence of a subpopulation of GABA binding sites, perhaps of low affinity for GABA, which is associated with barbiturate receptor sites. This subpopulation seems to correspond in brain regional distribution with the fraction of barbiturate-enhanced benzodiazepine binding sites which is sensitive to the GABA receptor antagonist bicuculline and thus apparently associated with GABA receptors (Olsen and Leeb-Lundberg, 1981; Leeb-Lundberg and Olsen, 1981, 1982b) .
Barbiturates enhanced GABA receptor binding using five different radioactive ligands. The barbiturate effects on GABA receptor binding were not significantly different at 37°C compared to 0°C using ["HIGABA or ["HI muscimol as the ligand. The more physiological temperature has been found to reveal a chloride potentiation of GABA enhancement of benzodiazepine binding (Ehlert et al., 1981) , a picrotoxinin blockade of GABA enhancement of benzodiazepine binding (Karobath et al., 1981) , and an enhancement of benzodiazepine binding by certain GABA analogues, such as P4S, which do not show the effect at 0°C in chloride-free medium (Supavilai and Karobath, 1980) . Whereas the base line binding with all ligands was almost the same at 0°C and 37°C the enhancement of [3H]P4S binding by pentobarbital was much greater at 37°C than at 0°C. It may be that this difference is related to the temperature effect observed for the P4S interaction with benzodiazepine binding (Supavilai and Karobath, 1980) . This provides another example of differences between GABA analogues in in vitro binding studies despite an apparently identical physiological action in viuo (Krogsgaard-Larsen et al., 1981) . These intriguing differences may provide clues to the action of these substances at the receptor level.
Note added inproof.
Other reports with similar results have appeared since the writing of this work (Whittle and Turner, 1982; Supavila et al., 1982) .
